These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 22528366)

  • 1. Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease.
    Elliott DA; Kim WS; Gorissen S; Halliday GM; Kwok JB
    Mov Disord; 2012 Jul; 27(8):1004-11. PubMed ID: 22528366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants.
    Xiromerisiou G; Hadjigeorgiou GM; Gourbali V; Johnson J; Papakonstantinou I; Papadimitriou A; Singleton AB
    Eur J Neurol; 2007 Jan; 14(1):7-11. PubMed ID: 17222106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease.
    Yonova-Doing E; Atadzhanov M; Quadri M; Kelly P; Shawa N; Musonda ST; Simons EJ; Breedveld GJ; Oostra BA; Bonifati V
    Parkinsonism Relat Disord; 2012 Jun; 18(5):567-71. PubMed ID: 22445250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients.
    Tan YY; Wu L; Zhao ZB; Wang Y; Xiao Q; Liu J; Wang G; Ma JF; Chen SD
    Parkinsonism Relat Disord; 2014 Mar; 20(3):308-13. PubMed ID: 24398085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls.
    Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
    Neurobiol Aging; 2015 Feb; 36(2):1105-9. PubMed ID: 25475535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microarray expression analysis in idiopathic and LRRK2-associated Parkinson's disease.
    Botta-Orfila T; Tolosa E; Gelpi E; Sànchez-Pla A; Martí MJ; Valldeoriola F; Fernández M; Carmona F; Ezquerra M
    Neurobiol Dis; 2012 Jan; 45(1):462-8. PubMed ID: 21946334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
    Qing H; Wong W; McGeer EG; McGeer PL
    Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.
    Ling H; Kara E; Bandopadhyay R; Hardy J; Holton J; Xiromerisiou G; Lees A; Houlden H; Revesz T
    Neurobiol Aging; 2013 Dec; 34(12):2889.e5-9. PubMed ID: 23664753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.
    Lesage S; Janin S; Lohmann E; Leutenegger AL; Leclere L; Viallet F; Pollak P; Durif F; Thobois S; Layet V; Vidailhet M; Agid Y; Dürr A; Brice A; ; Bonnet AM; Borg M; Broussolle E; Damier P; Destée A; Martinez M; Penet C; Rasco O; Tison F; Tranchan C; Vérin M
    Arch Neurol; 2007 Mar; 64(3):425-30. PubMed ID: 17353388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
    Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
    Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
    Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
    J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.
    Sharma S; Bandopadhyay R; Lashley T; Renton AE; Kingsbury AE; Kumaran R; Kallis C; Vilariño-Güell C; O'Sullivan SS; Lees AJ; Revesz T; Wood NW; Holton JL
    Neuropathol Appl Neurobiol; 2011 Dec; 37(7):777-90. PubMed ID: 21696411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
    Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
    Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 gene in Parkinson disease: mutation analysis and case control association study.
    Paisán-Ruíz C; Lang AE; Kawarai T; Sato C; Salehi-Rad S; Fisman GK; Al-Khairallah T; St George-Hyslop P; Singleton A; Rogaeva E
    Neurology; 2005 Sep; 65(5):696-700. PubMed ID: 16157901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic factors influencing age at onset in LRRK2-linked Parkinson disease.
    Golub Y; Berg D; Calne DB; Pfeiffer RF; Uitti RJ; Stoessl AJ; Wszolek ZK; Farrer MJ; Mueller JC; Gasser T; Fuchs J
    Parkinsonism Relat Disord; 2009 Aug; 15(7):539-41. PubMed ID: 19041274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the genetic variability in Parkinson's disease from Southern Spain.
    Bandrés-Ciga S; Mencacci NE; Durán R; Barrero FJ; Escamilla-Sevilla F; Morgan S; Hehir J; Vives F; Hardy J; Pittman AM
    Neurobiol Aging; 2016 Jan; 37():210.e1-210.e5. PubMed ID: 26518746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.